Performance of NBIX Neurocrine Biosciences | 42.7% in 12m
Compare NBIX with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Neurocrine Biosciences with its related Sector/Index XBI
Performance Duell NBIX vs XBI
| TimeFrame | NBIX | XBI |
|---|---|---|
| 1 Day | 0.63% | 1.86% |
| 1 Week | 3.47% | 7.77% |
| 1 Month | 2.27% | -1.16% |
| 3 Months | -0.73% | 2.28% |
| 6 Months | 25.1% | 25.94% |
| 12 Months | 42.7% | 8.16% |
| YTD | 6.82% | -0.28% |
| Rel. Perf. 1m | 0.41 | |
| Rel. Perf. 3m | 1.14 | |
| Rel. Perf. 6m | -0.43 | |
| Rel. Perf. 12m | 2.83 |
Is Neurocrine Biosciences a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Neurocrine Biosciences (NASDAQ:NBIX) is currently (May 2024)
ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 57.95 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NBIX as of May 2024 is 139.00. This means that NBIX is currently overvalued and has a potential downside of -1.22% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NBIX as of May 2024 is 139.00. This means that NBIX is currently overvalued and has a potential downside of -1.22% (Sold with Premium).
Is NBIX a buy, sell or hold?
- Strong Buy: 15
- Buy: 6
- Hold: 8
- Sell: 0
- Strong Sell: 0
Values above 0%: NBIX is performing better - Values below 0%: NBIX is underperforming
Compare NBIX with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 2.87% | 3.83% | 6.67% | 15.56% |
| US NASDAQ 100 | QQQ | 2.43% | 3.77% | 6.25% | 4.51% |
| US Dow Jones Industrial 30 | DIA | 2.30% | 3.37% | 10.52% | 24.68% |
| German DAX 40 | DBXD | 4.36% | 4.34% | 6.87% | 29.53% |
| UK FTSE 100 | ISFU | 1.81% | -0.94% | 10.77% | 33.23% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -0.04% | -1.36% | 21.93% | 52.46% |
| Hongkong Hang Seng | HSI | -2.29% | -5.79% | 26.34% | 56.55% |
| Japan Nikkei 225 | EXX7 | 1.12% | 7.08% | 11.52% | 22.27% |
| India NIFTY 50 | INDA | 2.69% | 0.24% | 5.71% | 13.57% |
| Brasil Bovespa | EWZ | 1.03% | 1.58% | 20.26% | 18.42% |
NBIX Neurocrine Biosciences vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 3.35% | 5.41% | 5.80% | 4.41% |
| Consumer Discretionary | XLY | 2.33% | 3.41% | 13.66% | 19.36% |
| Consumer Staples | XLP | 3.09% | 0.46% | 13.11% | 40.80% |
| Energy | XLE | 6.78% | 6.94% | 16.45% | 21.43% |
| Financial | XLF | 4.13% | 4.91% | 4.05% | 13.54% |
| Health Care | XLV | 2.85% | 4.49% | 13.71% | 35.42% |
| Industrial | XLI | 3.38% | 4.09% | 3.27% | 16.73% |
| Materials | XLB | 3.46% | 5.88% | 10.30% | 26.80% |
| Real Estate | XLRE | 1.93% | 5.94% | 17.85% | 37.72% |
| Technology | XLK | 2.11% | 4.60% | 6.76% | 4.94% |
| Utilities | XLU | 0.12% | -2.81% | 12.59% | 38.72% |
| Aerospace & Defense | XAR | 0.99% | 0.62% | 9.57% | 19.22% |
| Biotech | XBI | -4.30% | 3.43% | -0.80% | 34.52% |
| Homebuilder | XHB | 2.02% | 5.41% | -11.20% | -7.33% |
| Retail | XRT | 3.20% | 4.99% | 6.09% | 19.22% |
Does Neurocrine Biosciences outperform its market, is NBIX a Sector Leader?
Yes, over the last 12 months Neurocrine Biosciences (NBIX) made 42.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.16%.
Over the last 3 months NBIX made -0.73%, while XBI made 2.28%.
Yes, over the last 12 months Neurocrine Biosciences (NBIX) made 42.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.16%.
Over the last 3 months NBIX made -0.73%, while XBI made 2.28%.
| Period | NBIX | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 2.27% | -1.16% | -1.56% |
| 3 Months | -0.73% | 2.28% | 3.75% |
| 12 Months | 42.68% | 8.16% | 27.12% |